

Creating a New KISQALI Order Set

Oracle Cerner®

Maintaining up-to-date protocols in EHRs is an integral part of providing comprehensive, consistent care. To better support your health care organization, Novartis has developed this Oracle Cerner EHR Guide that can be used by your EHR support or information technology departments to develop, configure, and modify EHR components relevant to treatment with KISQALI.

Introduction

This guide provides an overview of how to create a new KISQALI Order Set within the Oracle Cerner EHR. KISQALI monitoring and dosing information is also included for reference. The navigation tabs at the top of each page can be used to easily navigate between information.

EHR=electronic health record.

Indications

KISQALI is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with:

- an aromatase inhibitor as initial endocrine-based therapy; or
- fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy in postmenopausal women or in men.

IMPORTANT SAFETY INFORMATION

QT interval prolongation. KISQALI has been shown to prolong the QT interval in a concentration-dependent manner. Based on the observed QT prolongation during treatment, KISQALI may require dose interruption, reduction, or discontinuation. Across KISQALI treatment groups, 15 of 1054 patients (1.4%) had >500 ms postbaseline QTcF value, and 61 of 1054 (6%) had a >60 ms increase from baseline in QTcF intervals. These electrocardiogram (ECG) changes were reversible with dose interruption and most occurred within the first 4 weeks of treatment. No cases of torsades de pointes were reported. In MONALEESA-2, on the KISQALI + letrozole treatment arm, there was 1 (0.3%) sudden death in a patient with grade 3 hypokalemia and grade 2 QT prolongation. No cases of sudden death were reported in MONALEESA-7 or MONALEESA-3.

Please see additional Important Safety Information throughout and [click here](#) for full Prescribing Information for KISQALI.



Upfront ECG Monitoring

ECG and QTcF Prolongation Overview

- **ECG** measures electrical impulses as 5 waves using the letters P, Q, R, S, and T.¹
- **QT interval** is the space between the start of the Q wave and end of the T wave, characterizing the electrical depolarization and repolarization of the heart's ventricles.^{1,2}
- **QTc** is a QT interval measurement corrected to compare QT intervals at different heart rates.²
- **QTcF** is a QT interval corrected using the Fridericia formula.³
- **Prolongation of the QTc interval** is a risk factor of developing torsades de pointes or other clinically significant arrhythmias.⁴
- **Risk factors for QT interval prolongation** include medications with risk of lengthening the QT interval, 4 electrolyte imbalances (hypokalemia, hypomagnesemia, hypophosphatemia, and hypocalcemia), age, sex, bradycardia, and family/personal medical history.⁴⁻⁶

KISQALI QTcF Prolongation Incidence³

Low incidence of QT prolongation across all KISQALI clinical trials, and most cases were moderate in nature

In a pooled analysis across 3 phase III trials of 1054 premenopausal and postmenopausal patients treated with KISQALI + an AI or fulvestrant:

1% had a >500 ms post baseline QTcF value

6% experienced a >60 ms increase from baseline in QTcF interval

- There were no reported cases of torsades de pointes

ECG changes were reversible with dose interruption and the majority occurred within the first 4 weeks of treatment.

AI=aromatase inhibitor.

IMPORTANT SAFETY INFORMATION (continued)

QT interval prolongation (continued). Assess ECG prior to initiation of treatment. Initiate treatment with KISQALI only in patients with QTcF values <450 ms. Repeat ECG at approximately Day 14 of the first cycle, at the beginning of the second cycle, and as clinically indicated. Monitor serum electrolytes (including potassium, calcium, phosphorus, and magnesium) prior to the initiation of treatment, at the beginning of each of the first 6 cycles, and as clinically indicated. Correct any abnormality before starting therapy with KISQALI.

Avoid the use of KISQALI in patients who already have or who are at significant risk of developing QT prolongation, including patients with:

- long QT syndrome
- uncontrolled or significant cardiac disease including recent myocardial infarction, congestive heart failure, unstable angina, and bradyarrhythmias
- electrolyte abnormalities

Avoid using KISQALI with drugs known to prolong the QT interval and/or strong CYP3A inhibitors, as this may lead to prolongation of the QTcF interval.

Please see additional Important Safety Information throughout and [click here](#) for full Prescribing Information for KISQALI.

Upfront ECG Monitoring (continued)³

ECG Monitoring		
Baseline		✓
Cycle 1	Day 14	✓
Cycle 2	Day 1	✓ (final scheduled)

- KISQALI should only be initiated in patients with QTcF <450 ms. In case of QTcF prolongation during therapy, more frequent monitoring is recommended
- Any additional monitoring should be performed as clinically indicated
- Monitoring requirements based on a 28-day treatment cycle

Only 3 ECGs are required—and all are completed within the first 30 days of treatment.

IMPORTANT SAFETY INFORMATION (continued)

Interstitial lung disease/pneumonitis. Severe, life-threatening, or fatal interstitial lung disease (ILD) and/or pneumonitis can occur in patients treated with KISQALI and other CDK4/6 inhibitors.

Across clinical trials in patients with advanced or metastatic breast cancer treated with KISQALI in combination with an aromatase inhibitor or fulvestrant ("KISQALI treatment groups"), 1.6% of patients treated with KISQALI had ILD/pneumonitis of any grade, 0.4% had grade 3/4, and 0.1% had a fatal outcome. Additional cases of ILD/pneumonitis have been observed in the postmarketing setting, with fatalities reported.

Monitor patients for pulmonary symptoms indicative of ILD/pneumonitis, which may include hypoxia, cough, and dyspnea. In patients who have new or worsening respiratory symptoms suspected to be due to ILD or pneumonitis, interrupt treatment with KISQALI immediately and evaluate the patient. Permanently discontinue treatment with KISQALI in patients with recurrent symptomatic or severe ILD/pneumonitis.

Severe cutaneous adverse reactions. Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS) can occur in patients treated with KISQALI.

If signs or symptoms of SCARs occur, interrupt KISQALI until the etiology of the reaction has been determined. Consultation with a dermatologist is recommended.

If SJS, TEN, or DiHS/DRESS is confirmed, permanently discontinue KISQALI. Do not reintroduce KISQALI in patients who have experienced SCARs or other life-threatening cutaneous reactions during KISQALI treatment.

Please see additional Important Safety Information throughout and [click here](#) for full Prescribing Information for KISQALI.

Routine Laboratory Monitoring³

		CBC/LFT	Electrolytes
Baseline		✓	✓
Cycle 1	Day 14	✓	
Cycle 2	Day 1	✓	✓
	Day 14	✓	
Cycle 3-6	Day 1	✓	✓

- For LFTs, if grade ≥ 2 abnormalities are noted, more frequent monitoring is recommended
- Correct any electrolyte abnormalities prior to treatment
- Additional monitoring may be required as clinically indicated
- Monitoring requirements based on a 28-day treatment cycle

The majority of scheduled monitoring occurs within the first 2 cycles of therapy and there is no scheduled monitoring beyond Cycle 6.

CBC=complete blood count; LFT=liver function test.

IMPORTANT SAFETY INFORMATION (continued)

Increased QT prolongation with concomitant use of tamoxifen. KISQALI is not indicated for concomitant use with tamoxifen. In MONALEESA-7, the observed mean QTcF increase from baseline was ≥ 10 ms higher in the tamoxifen + placebo subgroup compared with the non-steroidal aromatase inhibitor (NSAI) + placebo subgroup. In the placebo arm, an increase of >60 ms from baseline occurred in 6/90 (7%) of patients receiving tamoxifen, and in no patients receiving an NSAI. An increase of >60 ms from baseline in the QTcF interval was observed in 14/87 (16%) of patients in the KISQALI and tamoxifen combination and in 18/245 (7%) of patients receiving KISQALI plus an NSAI.

Please see additional Important Safety Information throughout and [click here](#) for full Prescribing Information for KISQALI.



Monitoring Summary³

		Upfront ECG Monitoring	Routine Laboratory Monitoring	
		ECG Monitoring	CBC/LFT	Electrolytes
Baseline		✓	✓	✓
Cycle 1	Day 14	✓	✓	
Cycle 2	Day 1	✓	✓	✓
	Day 14		✓	
Cycle 3-6	Day 1		✓	✓

LAB

The majority of scheduled monitoring occurs **within the first 2 cycles of therapy** and there is **no scheduled monitoring beyond Cycle 6**.

ECG

Only 3 ECGs are required—and all are completed within the **first 30 days of treatment**.

IMPORTANT SAFETY INFORMATION (continued)

Hepatobiliary toxicity. Across KISQALI treatment groups, increases in transaminases were observed. Across all trials, grade 3/4 increases in alanine aminotransferase (ALT) (11% vs 2.1%) and aspartate aminotransferase (AST) (8% vs 2%) were reported in the KISQALI and placebo arms, respectively.

Among the patients who had grade ≥ 3 ALT/AST elevation, the median time to onset was 92 days and median time to resolution to grade ≤ 2 was 21 days for the KISQALI treatment groups.

Please see additional Important Safety Information throughout and [click here](#) for full Prescribing Information for KISQALI.

Dosing³

KISQALI—the only CDK4/6 inhibitor that offers one tablet strength for simple dose reductions

Recommended starting dose



1st reduction



2nd reduction



- KISQALI is given as 600 mg (3 x 200-mg tablets) orally once daily (3 weeks on, 1 week off) with either:
 - An AI once daily (continuously); in premenopausal patients and men, an LHRH agonist should be administered according to current clinical practice guidelines; or
 - Fulvestrant 500 mg intramuscularly on Days 1, 15, and 29, and once monthly thereafter for postmenopausal patients or men. In male patients, an LHRH agonist should be administered according to current clinical practice guidelines
- Dose adjustments for adverse reactions should be made in a stepwise order by reducing the number of tablets taken
- Dose modification of KISQALI is recommended based on individual safety and tolerability
- If dose reduction below 200 mg/day is required, discontinue treatment
- KISQALI can be taken with or without food

**Simple dose reductions with no need for a new prescription
or additional cost to patient mid-cycle**

LHRH=luteinizing hormone-releasing hormone.

IMPORTANT SAFETY INFORMATION (continued)

Hepatobiliary toxicity (continued). In MONALEESA-2 and MONALEESA-3, concurrent elevations in ALT or AST greater than 3 times the upper limit of normal (ULN) and total bilirubin greater than 2 times the ULN, with normal alkaline phosphatase, in the absence of cholestasis occurred in 6 (1%) patients and all patients recovered after discontinuation of KISQALI. No cases occurred in MONALEESA-7.

Perform liver function tests (LFTs) before initiating therapy with KISQALI. Monitor LFTs every 2 weeks for the first 2 cycles, at the beginning of each of the subsequent 4 cycles, and as clinically indicated. Based on the severity of the transaminase elevations, KISQALI may require dose interruption, reduction, or discontinuation. Recommendations for patients who have elevated AST/ALT grade ≥ 3 at baseline have not been established.

Please see additional Important Safety Information throughout and [click here](#) for full Prescribing Information for KISQALI.



EHR Build Guide: Order Sets

Order Sets Overview

Order Sets:

- Allow for specific groups of orders to be displayed and placed from one location within the ordering window
- May be added to clinical specialty folders and provider favorites/preference lists to streamline ordering workflow

Order Set Instructions

To create a new KISQALI order set:

Step 1: Configure Clinical Sub Categories

Step 2: Create New Plan

Step 3: Configure plan and/or phase attributes

Step 4: Configure plan components

Detailed Order Set Instructions

Step 1: Configure Clinical Sub Categories: Orders and Medications

- From the PowerPlan window pane, select the Orders tab
- Search for all appropriate lab orders and ECG procedure orders, according to the organization's order configuration and enter the applicable clinical category, clinical sub category, and order sentence information



Note: To nest order sentences under an order synonym, add the order synonym (with appropriate clinical and sub clinical categories), then access the attribute window pane. From the attribute window pane, right-click the "Order Sentence" value, select "Add," and enter applicable information.

IMPORTANT SAFETY INFORMATION (continued)

Neutropenia. Across KISQALI treatment groups neutropenia was the most frequently reported adverse reaction (AR) (75%), and a grade 3/4 decrease in neutrophil count (based on laboratory findings) was reported in 62% of patients in the KISQALI treatment groups. Among the patients who had grade 2, 3, or 4 neutropenia, the median time to grade ≥ 2 was 17 days. The median time to resolution of grade ≥ 3 (to normalization or grade < 3) was 12 days in the KISQALI treatment groups. Febrile neutropenia was reported in 1.7% of patients in the KISQALI treatment groups. Treatment discontinuation due to neutropenia was 1%.

Please see additional Important Safety Information throughout and [click here](#) for full Prescribing Information for KISQALI.

Step 2. Create New Plan

- Within the PowerPlan Tool window, click the Create New Plan icon
- From the Add a Plan dialog box, enter applicable information for each of the following:
 - Plan Name: (eg, KISQALI Order Set)
 - Display Method: (eg, Clinical Category)
 - Single Phase / Multiple Phase: (eg, Single Phase)
 - Status: (eg, Testing)
 - Plan Type: (eg, Medical)



Note: Phase, Plan Type, and Display Method may vary for each plan and should be created, modified, or adjusted accordingly to ensure all applicable aspects are incorporated.

Step 3: Configure Plan and/or Phase Attributes

From the Attribute Name window pane, adjust the following Values as applicable:

- Status
- Reference Text
- Evidence Link
- Facility Flexing
- Sub Phase
- Allow Diagnosis Propagation
- Hide Flexed Components
- Cycle Settings
- Default View
- Prompt for Ordering Physician
- Copy Forward
- Related Results
- Check Alerts on Planning
- Check Alerts on Plan Updates
- Classification
- Plan Ordering Defaults
- Route for Review
- Document Reschedule Reason
- Build Linked Components Group
- Do Not Allow Proposal



Note: Attribute values may vary for each plan and can also be defined for individual.

Step 4: Configure Plan Components

- From the PowerPlan window pane, select the Note tab
- Select the appropriate Clinical Category and Clinical Sub Categories from the drop down menus
- Add desired note content for each applicable Clinical Sub Category



Note: To allow a note to be displayed at all times the “Persistent” attribute value flag should be enabled. Note: Reference text can be added by selecting the “Reference Text” icon from the PowerPlan Tool menu bar.

Note: Clinical category and clinical sub category should be selected from the drop down when adding each order to ensure the appropriate categorization structure within the plan.

IMPORTANT SAFETY INFORMATION (continued)

Neutropenia (continued). Perform complete blood count (CBC) before initiating therapy with KISQALI. Monitor CBC every 2 weeks for the first 2 cycles, at the beginning of each of the subsequent 4 cycles, and as clinically indicated. Based on the severity of the neutropenia, KISQALI may require dose interruption, reduction, or discontinuation.

Please see additional Important Safety Information throughout and [click here](#) for full Prescribing Information for KISQALI.

Notes

- The Customers (ie, physician, medical group, integrated delivery network [IDN]) shall be solely responsible for implementation, testing, and monitoring of the instructions to ensure proper orientation in each Customer's EHR system
- Capabilities, functionality, and setup (customization) for each individual EHR system vary. Novartis shall not be responsible for revising the implementation instructions it provides to any Customer in the event that Customer modifies or changes its software, or the configuration of its EHR system, after such time as the implementation instructions have been initially provided by Novartis
- While Novartis tests its implementation instructions on multiple EHR systems, the instructions are not guaranteed to work for all available EHR systems and Novartis shall have no liability thereto
- The instructions have not been designed to meet and are not tools and/or solutions for meeting Meaningful Use, Advancing Care Information, and/or any other quality/accreditation requirement
- All products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Novartis and/or its affiliates

For more information on how the Novartis HIT Team can collaborate with your organization to identify shared priorities please email: HIT.Novartis@novartis.com.

HIT=health information technology

Oracle Cerner® is a registered trademark of the Oracle Cerner Corporation.

IMPORTANT SAFETY INFORMATION (continued)

Embryo-fetal toxicity. Based on findings from animal studies and the mechanism of action, KISQALI can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of KISQALI to pregnant rats and rabbits during organogenesis caused embryo-fetal toxicities at maternal exposures that were 0.6 and 1.5 times the human clinical exposure, respectively, based on area under the curve. Advise pregnant women of the potential risk to a fetus. Advise women of reproductive potential to use effective contraception during therapy with KISQALI and for at least 3 weeks after the last dose.

Please see additional Important Safety Information throughout and [click here](#) for full Prescribing Information for KISQALI.



IMPORTANT SAFETY INFORMATION (continued)

Adverse reactions. Most common (incidence $\geq 20\%$) adverse reactions include infections, nausea, fatigue, diarrhea, vomiting, headache, constipation, alopecia, cough, rash, and back pain.

Laboratory abnormalities. Across clinical trials of patients with advanced or metastatic breast cancer, the most common laboratory abnormalities reported in the KISQALI arm (all grades, pooled incidence $\geq 20\%$) **were leukocytes decreased, neutrophils decreased, hemoglobin decreased, lymphocytes decreased, AST increased, gamma-glutamyl transferase increased, ALT increased, creatinin increased, platelets decreased, and glucose serum decreased.**

References: **1.** Mayo Clinic. Long QT syndrome diagnosis & treatment. <https://www.mayoclinic.org/diseases-conditions/long-qt-syndrome/diagnosis-treatment/drc-20352524>. Accessed July 27, 2023. **2.** Vandenberk B, et al. *J Am Heart Assoc.* 2016;5(6):e003264. **3.** KISQALI. Prescribing Information. Novartis Pharmaceuticals Corp. **4.** Mayo Clinic. Long QT syndrome symptoms & causes. <https://www.mayoclinic.org/diseases-conditions/longqt-syndrome/symptoms-causes/syc-20352518>. Accessed July 27, 2023. **5.** Al-Khatib SM, et al. *JAMA.* 2003;289(16):2120-2127. **6.** Vered I, et al. *J Bone Miner Res.* 1990;5(5):469-474.

Please see additional Important Safety Information throughout and [click here](#) for full Prescribing Information for KISQALI.

